spacer
spacer

PDBsum entry 2zv8

Go to PDB code: 
protein ligands links
Transferase PDB id
2zv8

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
257 a.a. *
Ligands
ANP
Waters ×15
* Residue conservation analysis
PDB id:
2zv8
Name: Transferase
Title: Lyn tyrosine kinase domain-amp-pnp complex
Structure: Tyrosine-protein kinase lyn. Chain: a. Fragment: kinase domain, residues 239-512. Engineered: yes
Source: Mus musculus. Mouse. Organism_taxid: 10090. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108.
Resolution:
2.70Å     R-factor:   0.201     R-free:   0.245
Authors: N.K.Williams,J.Rossjohn
Key ref:
N.K.Williams et al. (2009). Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state. J Biol Chem, 284, 284-291. PubMed id: 18984583 DOI: 10.1074/jbc.M807850200
Date:
04-Nov-08     Release date:   11-Nov-08    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P25911  (LYN_MOUSE) -  Tyrosine-protein kinase Lyn from Mus musculus
Seq:
Struc:
512 a.a.
257 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 2 residue positions (black crosses)

 Enzyme reactions 
   Enzyme class: E.C.2.7.10.2  - non-specific protein-tyrosine kinase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
L-tyrosyl-[protein]
+ ATP
= O-phospho-L-tyrosyl-[protein]
Bound ligand (Het Group name = ANP)
matches with 81.25% similarity
+ ADP
+ H(+)
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    Added reference    
 
 
DOI no: 10.1074/jbc.M807850200 J Biol Chem 284:284-291 (2009)
PubMed id: 18984583  
 
 
Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
N.K.Williams, I.S.Lucet, S.P.Klinken, E.Ingley, J.Rossjohn.
 
  ABSTRACT  
 
The Src-family protein-tyrosine kinase (PTK) Lyn is the most important Src-family kinase in B cells, having both inhibitory and stimulatory activity that is dependent on the receptor, ligand, and developmental context of the B cell. An important role for Lyn has been reported in acute myeloid leukemia and chronic myeloid leukemia, as well as certain solid tumors. Although several Src-family inhibitors are available, the development of Lyn-specific inhibitors, or inhibitors with reduced off-target activity to Lyn, has been hampered by the lack of structural data on the Lyn kinase. Here we report the crystal structure of the non-liganded form of Lyn kinase domain, as well as in complex with three different inhibitors: the ATP analogue AMP-PNP; the pan Src kinase inhibitor PP2; and the BCR-Abl/Src-family inhibitor Dasatinib. The Lyn kinase domain was determined in its "active" conformation, but in the unphosphorylated state. All three inhibitors are bound at the ATP-binding site, with PP2 and Dasatinib extending into a hydrophobic pocket deep in the substrate cleft, thereby providing a basis for the Src-specific inhibition. Analysis of sequence and structural differences around the active site region of the Src-family PTKs were evident. Accordingly, our data provide valuable information for the further development of therapeutics targeting Lyn and the important Src-family of kinases.
 
  Selected figure(s)  
 
Figure 2.
Overview of the crystal structure of Lyn. A, ribbon representation of the crystal structure of Lyn PTK. The N-terminal lobe (residues 239–326) shown in gray comprises a five-stranded anti-parallel β-sheet and one α-helix (αC). The C-terminal lobe (residues 327–501) is shown in green. The glycine loop is colored in orange, the hinge region between the two lobes in yellow, the catalytic loop in blue, and the activation loop in red. B, close-up of portions of the αC helix and activation loop showing active (Lyn (blue), Lck (yellow)) and inactive (Src (magenta), Hck (green)) conformations.
Figure 3.
Mode of inhibitors binding to Lyn PTK. A, interaction between AMP-PNP and Lyn PTK. B, interaction between PP2 and Lyn PTK. C, interaction between Dasatinib and Lyn PTK. Left panel, the side chains of residues that interact with the inhibitor are shown, as are main-chain atoms and water molecules participating in hydrogen bonds. Right panel, corresponding view of the inhibitor in a ball-and-stick representation and covered with the simulated annealing omit-map Fo-Fc electron density map contoured at 2σ.
 
  The above figures are reprinted by permission from the ASBMB: J Biol Chem (2009, 284, 284-291) copyright 2009.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
  21463117 P.C.Amrein (2011).
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
  Leuk Lymphoma, 52, 754-763.  
  20052711 D.J.Marcotte, Y.T.Liu, R.M.Arduini, C.A.Hession, K.Miatkowski, C.P.Wildes, P.F.Cullen, V.Hong, B.T.Hopkins, E.Mertsching, T.J.Jenkins, M.J.Romanowski, D.P.Baker, and L.F.Silvian (2010).
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.
  Protein Sci, 19, 429-439.
PDB codes: 3gen 3k54
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.

 

spacer

spacer